Ferozsons to manufacture first authorized generic

Ferozsons Laboratories Limited has recently obtained the manufacturing license along with requisite production process technology from Gilead Sciences, Inc. to manufacture an authorized generic of the breakthrough Hepatitis C Virus (HCV) treatment in Pakistan.

The generic treatment is priced at a fraction of the originator access price in Pakistan. With this approval, Ferozsons is furthering its mission to expand the cure to new patients suffering from this deadly disease.

Availability of this authorized generic version of the HCV treatment at such a reduced price will further expand quality treatment access to HCV cure for patients in Pakistan.